Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Marie-Josée J Mangen; Mark H Rozenbaum; Susanne M Huijts; Cornelis H van Werkhoven; Douwe F Postma; Mark Atwood; Anna M M van Deursen; Arie van der Ende; Diederick E Grobbee; Elisabeth A M Sanders; Reiko Sato; Theo J M Verheij; Conrad E Vissink; Marc J M Bonten; G Ardine de Wit

doi:10.1183/13993003.00325-2015

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Marie-Josée J Mangen, Mark H Rozenbaum, Susanne M Huijts, Cornelis H van Werkhoven, Douwe F Postma, Mark Atwood, Anna M M van Deursen, Arie van der Ende, Diederick E Grobbee, Elisabeth A M Sanders, Reiko Sato, Theo J M Verheij, Conrad E Vissink, Marc J M Bonten, G Ardine de Wit

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750-17 100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

Original language	English
Pages (from-to)	1407-1416
Number of pages	10
Journal	European Respiratory Journal
Volume	46
Issue number	5
DOIs	https://doi.org/10.1183/13993003.00325-2015
Publication status	Published - Nov 2015

Access to Document

10.1183/13993003.00325-2015

Cite this

Mangen, M.-J. J., Rozenbaum, M. H., Huijts, S. M., van Werkhoven, C. H., Postma, D. F., Atwood, M., van Deursen, A. M. M., van der Ende, A., Grobbee, D. E., Sanders, E. A. M., Sato, R., Verheij, T. J. M., Vissink, C. E., Bonten, M. J. M., & de Wit, G. A. (2015). Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. European Respiratory Journal, 46(5), 1407-1416. https://doi.org/10.1183/13993003.00325-2015

@article{68d0d3962f264b21934344ff432cb431,

title = "Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands",

abstract = "The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750-17 100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.",

author = "Mangen, {Marie-Jos{\'e}e J} and Rozenbaum, {Mark H} and Huijts, {Susanne M} and {van Werkhoven}, {Cornelis H} and Postma, {Douwe F} and Mark Atwood and {van Deursen}, {Anna M M} and {van der Ende}, Arie and Grobbee, {Diederick E} and Sanders, {Elisabeth A M} and Reiko Sato and Verheij, {Theo J M} and Vissink, {Conrad E} and Bonten, {Marc J M} and {de Wit}, {G Ardine}",

note = "Copyright {\textcopyright}ERS 2015.",

year = "2015",

month = nov,

doi = "10.1183/13993003.00325-2015",

language = "English",

volume = "46",

pages = "1407--1416",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Mangen, M-JJ, Rozenbaum, MH, Huijts, SM, van Werkhoven, CH, Postma, DF, Atwood, M, van Deursen, AMM, van der Ende, A, Grobbee, DE , Sanders, EAM, Sato, R, Verheij, TJM, Vissink, CE, Bonten, MJM & de Wit, GA 2015, 'Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands', European Respiratory Journal, vol. 46, no. 5, pp. 1407-1416. https://doi.org/10.1183/13993003.00325-2015

TY - JOUR

T1 - Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

AU - Mangen, Marie-Josée J

AU - Rozenbaum, Mark H

AU - Huijts, Susanne M

AU - van Werkhoven, Cornelis H

AU - Postma, Douwe F

AU - Atwood, Mark

AU - van Deursen, Anna M M

AU - van der Ende, Arie

AU - Grobbee, Diederick E

AU - Sanders, Elisabeth A M

AU - Sato, Reiko

AU - Verheij, Theo J M

AU - Vissink, Conrad E

AU - Bonten, Marc J M

AU - de Wit, G Ardine

PY - 2015/11

Y1 - 2015/11

N2 - The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750-17 100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

AB - The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750-17 100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

U2 - 10.1183/13993003.00325-2015

DO - 10.1183/13993003.00325-2015

M3 - Article

C2 - 26160871

SN - 0903-1936

VL - 46

SP - 1407

EP - 1416

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

ER -

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Abstract

Access to Document

Fingerprint

Cite this